Mast Cell Derived Histamine Negatively Regulates Hematopoiesis.

Authors

Bailey R Klein, Julianne N P Smith, Ramachandra Katabathula, Ritisha Rashmil, Sofia X Wilhelm, Rahul Chaudhary, Karina Inacio Ladislau De Carvalho, Zhenxiang Gao, Brittany A Cordova, Eric E Irons, Benjamin Kovacic, Shikha Parsai, Vladimir Makarov, Frederick Petroze, Riya Tiwari, Stanton L Gerson, Rong Xu, Sanford D Markowitz, Amar B Desai

Published in

Experimental hematology. Pages 105893. Sep 03, 2026. Epub Sep 03, 2026.

Abstract

Mast cells (MCs) are well known for their roles in immunity, but their influence on hematopoietic stem cell (HSC) regulation remains poorly defined. Here, we identify MC-derived histamine as a suppressor of hematopoiesis. MC-deficient "SASH" mice exhibited increased bone marrow HSC frequency, a transcriptional quiescence signature, and resistance to myeloablative chemotherapy, associated with niche remodeling, including increased HSC-supportive stromal populations and elevated maintenance factor expression, and improved engraftment of wild-type donor cells. Reciprocal transplants showed this phenotype is driven by the recipient niche rather than an HSC-intrinsic property, and MC-derived secretory factors were directly sufficient to suppress HSCs in vitro and in vivo. Pharmacologic H1 receptor blockade with cetirizine, an FDA-approved inverse agonist, phenocopied the SASH model, expanding HSCs and enhancing both early recovery and long-term reconstitution in transplant settings, while exogenous histamine reversed the SASH phenotype. Supporting clinical relevance, electronic health record analysis revealed that antihistamine use was associated with elevated white blood cell counts in humans. These findings establish mast cell-derived histamine as a suppressor of hematopoiesis and suggest that H1R antagonism may offer a tractable strategy to enhance hematopoietic regeneration. Teaser Abstract: Mast cell-derived histamine restrains hematopoietic stem cell activity by shaping the bone marrow niche. Blocking histamine signaling with the FDA-approved antihistamine cetirizine expands the stem and progenitor pool and accelerates hematopoietic recovery after transplant, pointing to a repurposable strategy for boosting blood regeneration in patients.

PMID:
42692326
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.